Furthermore, 60.3% of participants had widespread Aβ pathology (Thal phase of 5), 63.5% had a tau spread beyond the temporal lobes (Braak stage > IV), 74.6% had a neuritic plaque score of 3, and 60.3% had Alzheimer’s disease neuropathologic change (ADNC) of 3. Here, MAPT is linked to Alzheimer disease.